Skip to content

Comparison of Bowel Cleansing Efficacy Between Same-day Dose Versus Split Dose

Comparison of Bowel Cleansing Efficacy Between Same-day Dose Versus Split Dose : A Single Center, Operator Blinded, Prospective Randomized Controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03315949
Enrollment
352
Registered
2017-10-20
Start date
2017-05-01
Completion date
2018-02-28
Last updated
2020-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unrecognized Condition

Brief summary

Split dose bowel cleansing is recommended method for colonoscopy. For afternoon colonoscopy, same-day dose of bowel cleansing is alternative option. Recently, same-day bowel cleansing for morning colonoscopy was validated. To date, there was no study which compared the bowel cleansing efficacy between same-day dose and split dose regardless of colonoscopy time. The aim of current study is to compare the bowel cleansing efficacy, adverse events, and patient's tolerability between the two group. Subjects who underwent colonoscopy for various reasons were included. After agreeing to participate in the study, study participants were randomly assigned to split dose or same day dose group. Bowel cleansing is done using polyethylene glycol (PEG). All colonoscopy was done between 10 AM to 6 PM. Study participants were instructed to ingest 500ml PEG every 15 minutes. Subjects who were assigned to split dose group ingested 2L PEG from 9PM 1 day before colonoscopy. Remaining 2L PEG was ingested 3-5 hours before colonoscopy. In the same-day dose group, bowel cleansing was started from 5AM for subjects who were scheduled to receive colonoscopy in the morning. Afternoon colonoscopy group in the same-day dose group ingested 2L PEG from 5AM. Remaining 2L PEG was finished 3-5 hours before colonoscopy. Bowel cleansing efficacy was assessed using Boston bowel preparation scale. Vital signs and laboratory tests were checked before colonoscopy. Study participants completed questionnaire which contained patient's satisfaction, tolerability, and adverse event during bowel cleansing. Bowel cleansing efficacy, patient's tolerability, and safety profile were compared between the two groups. Successful bowel cleansing was estimated 85% for split dose group. The investigators set 10% for inferior margin. Considering 10% drop out, a total of 352 subjects will be recruited.

Detailed description

Randomization and blinding: Randomization will be done using computer generated randomization list. A specialized nurse will explain the method of bowel cleansing. Investigators (endoscopists) are blinded to bowel cleansing method. Endpoint: Primary end point is successful bowel cleansing rated by Boston bowel preparation (BBPS) scale. Successful bowel cleansing is defined as all segment is 2 or 3 points. Endoscopists will assess BBPS when colonoscopy withdrawal. Secondary end point was patient's tolerability and safety profile including adverse events. Patient's satisfaction to the different bowel cleansing method and adverse events (nausea, vomiting, dizziness, fatigue) will be investigated by questionnaire before colonoscopy. Blood test will be done before colonoscopy. Statistical analysis: Bowel cleansing success, patient's tolerability and safety profile will be compared between the two groups. Student t test for continuous variables and the chi-square test or Fisher exact test for categorical variables. Sample size: This study is non-inferioty study. Assuming bowel cleansing success rate 85% in the split-dose group, the significant difference between the two groups were hypothesized at 10%. Considering 80% power and 10% drop rate, a total of 352 participants is needed.

Interventions

Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy

Sponsors

Incheon St.Mary's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* all subjects who undergo colonoscopy for various reasons.

Exclusion criteria

* hemodynamic instability * ileus or bowel obstruction * active inflammatory bowel disease * advanced colon cancer

Design outcomes

Primary

MeasureTime frameDescription
Boston Bowel Preparation ScaleBowel cleansing efficacy using Boston bowel preparation scale will be assessed during colonoscopy withdrawalPrimary endpoint=Successful bowel cleansing (all segmental score 2 or above) \* Boston bowel preparation scale (0-9) Sum of 3 segment of bowel. 0=inadequate 1. poor 2. good 3. excellent

Countries

South Korea

Participant flow

Participants by arm

ArmCount
Same-day Dose Group
Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy. Polyethylene Glycol (PEG): Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy
172
Split-dose Group
Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy. Polyethylene Glycol (PEG): Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy
167
Total339

Baseline characteristics

CharacteristicSame-day Dose GroupSplit-dose GroupTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
50 Participants45 Participants95 Participants
Age, Categorical
Between 18 and 65 years
122 Participants122 Participants244 Participants
Age, Continuous57.7 years
STANDARD_DEVIATION 8.5
58.4 years
STANDARD_DEVIATION 9.4
58.0 years
STANDARD_DEVIATION 9
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
172 Participants167 Participants339 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Region of Enrollment
South Korea
172 participants167 participants339 participants
Sex: Female, Male
Female
72 Participants72 Participants144 Participants
Sex: Female, Male
Male
100 Participants95 Participants195 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1720 / 167
other
Total, other adverse events
73 / 17267 / 167
serious
Total, serious adverse events
0 / 1720 / 167

Outcome results

Primary

Boston Bowel Preparation Scale

Primary endpoint=Successful bowel cleansing (all segmental score 2 or above) \* Boston bowel preparation scale (0-9) Sum of 3 segment of bowel. 0=inadequate 1. poor 2. good 3. excellent

Time frame: Bowel cleansing efficacy using Boston bowel preparation scale will be assessed during colonoscopy withdrawal

ArmMeasureValue (NUMBER)
Same-day Dose GroupBoston Bowel Preparation Scale169 Number of successful cleansing
Split-dose GroupBoston Bowel Preparation Scale163 Number of successful cleansing

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026